Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma (Nasdaq: PPCB) has requested a foreign filing license from Spain for two provisional patents covering methods to treat resistant cancer and fibrosis.

Rhea-AI Summary

Propanc Biopharma (Nasdaq: PPCB) has requested a foreign filing license from Spain for two provisional patents covering methods to treat resistant cancer and fibrosis. The provisional patents will be filed with IP Australia under Propanc Pty Ltd and are expected to be pursued in key global jurisdictions.

The fibrosis provisional is described as a world-first expansion of PRP proenzyme therapy beyond cancer. Propanc says its planned Phase 1b First‑In‑Human study in 2026 will define PRP dosing ahead of Phase 2 proof‑of‑concept studies.

Positive

• Submitted foreign filing license request to Spain for two provisional patents
• Provisional patents to be filed with IP Australia under Propanc Pty Ltd
• Planned Phase 1b First‑In‑Human PRP study scheduled for 2026

Negative

• Provisional patents only; no patent grants reported yet
• Clinical development still pre‑Phase 2; efficacy not yet demonstrated in humans

Argus Dec 1 session

+5.47% close to close Open Argus

Details

News Market Reaction – PPCB

In the Dec 1 session, PPCB gained 5.47%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with the company’s effort to broaden PRP’s scope beyond oncology, as seen in the new provisional patents for resistant cancer and fibrosis. Historical data show that most prior positive updates were followed by selling, with 4 of 5 recent news events posting negative next‑day moves. Investors may weigh this pattern alongside financing-related dilution risk and the long lead time to the planned 2026 Phase 1b trial when assessing sustainability.

Key Figures

Post-MI life expectancy: 3–8 years Lung fibrosis survival: 3–5 years Phase 1b timing: 2026 +2 more

Post-MI life expectancy

3–8 years

Life expectancy after myocardial infarction-related scarring (ages 65–74)

Lung fibrosis survival

3–5 years

Typical life expectancy for lung fibrosis patients

Phase 1b timing

2026

Planned First-In-Human PRP Phase 1b study start year

Patent count

Two provisional patents

Methods to treat resistant cancer and fibrosis

Organ systems affected

Lungs, liver, kidneys, heart

Organs potentially impacted by fibrosis per article

Historical Context

5 past events · Latest: Dec 04

5 events

1. Dec 04

   Research program update

   24h Move

   -4.3%

   Announced EMT-focused research and PRP fibrotic patent plus 2026 Phase 1b plan.

2. Dec 01

   IP filing update

   24h Move

   +5.5%

   Requested Spanish foreign filing license for cancer and fibrosis patents.

3. Nov 17

   Earnings & corporate update

   24h Move

   -2.8%

   Reported Q1 results, PRP trial prep, GMP progress, and recent financings.

4. Nov 10

   Private placement deal

   24h Move

   -12.4%

   Secured up to $100M Series C preferred financing and warrants with Hexstone.

5. Nov 04

   Acquisition strategy

   24h Move

   -6.2%

   Announced plan to acquire digital asset treasury companies trading below MNAV.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fibrosis, extracellular matrix (ECM), myocardial infarction, epithelial-to-mesenchymal transition (EMT), +2 more

6 terms

fibrosis medical

"The second provisional patent relates to compositions, methods, uses, and kits for the treatment of fibrosis, particularly organ fibrosis."

Fibrosis is the process where excess scar tissue forms in an organ or tissue, often as a response to injury or long-term damage. This buildup can impair normal function, much like thickening insulation reduces the effectiveness of a wire. For investors, fibrosis is significant because it can signal ongoing health issues that may lead to increased medical costs or influence a company’s performance in healthcare-related sectors.

extracellular matrix (ECM) medical

"due to over-deposition of extracellular matrix (ECM) components, leading to stiffening"

A network of proteins and sugars that surrounds and supports cells, like the scaffold and soil that hold plants in place and send signals about growth and repair. Investors care because changes or damage to this matrix drive many diseases and are targets for drugs, diagnostics, and medical devices; therapies or products that modify or use the matrix can create substantial clinical and commercial value.

myocardial infarction medical

"For example, life expectancy following myocardial infarction-related scarring ranges from 3 to 8 years"

Myocardial infarction, commonly called a heart attack, happens when blood flow to part of the heart is suddenly blocked and heart muscle is damaged—like a garden hose being pinched so a patch of lawn starts to die. For investors, heart attacks matter because they drive demand for drugs, devices, hospitals and rehabilitation, affect health-care costs and workforce productivity, and can lead to regulatory actions, litigation or shifts in insurance and pricing that impact company earnings.

epithelial-to-mesenchymal transition (EMT) medical

"In particular, the epithelial-to-mesenchymal transition (EMT), a biological process central to embryogenesis"

Epithelial-to-mesenchymal transition (EMT) is a biological process where cells change from a structured, stationary state to a more flexible and mobile form. This transformation allows cells to move and invade new areas, similar to how a fixed building might turn into a mobile structure. Understanding EMT is important because it plays a role in processes like healing, development, and disease progression, which can impact health and, indirectly, influence market trends related to healthcare and biotech sectors.

Phase 1b medical

"Our planned Phase 1b, First-In-Human study in 2026 will define the target therapeutic dose"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

First-In-Human medical

"Our planned Phase 1b, First-In-Human study in 2026 will define the target therapeutic dose"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MELBOURNE, Australia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced that it has submitted a request for a foreign filing license from Spain for two provisional patents detailing new methods to treat resistant cancer and fibrosis. The patents will be filed with IP Australia under Propanc Pty Ltd, the Company’s wholly owned operating subsidiary based in Melbourne, Australia. These discoveries stem from Propanc’s Joint Research and Drug Discovery program with the Universities of Jaén and Granada in Spain and are expected to be filed subsequently in key global jurisdictions.

The first provisional patent covers methods for treating cancers that have developed resistance to chemotherapy and/or radiotherapy. Despite advancements in cancer therapies, global mortality rates remain high, and strategies to prevent recurrence are urgently needed. Treatment failure frequently occurs due to the emergence of multiple malignancies and resistance to standard therapies, underscoring the need for novel approaches.

The second provisional patent relates to compositions, methods, uses, and kits for the treatment of fibrosis, particularly organ fibrosis. Fibrosis is characterized by the excessive accumulation of scar tissue due to over-deposition of extracellular matrix (ECM) components, leading to stiffening, loss of function, and structural disruption of affected tissues. This maladaptive response can result from chronic injury or persistent inflammation and can impact nearly any organ system, including the lungs, liver, kidneys, and heart—contributing significantly to morbidity and mortality. Causes may include chronic inflammation, autoimmune and allergic responses, chemical insults, radiation, and tissue damage. For example, life expectancy following myocardial infarction-related scarring ranges from 3 to 8 years (ages 65–74), and for lung fibrosis patients is typically 3 to 5 years.

This fibrosis-related patent represents a world-first in Propanc’s intellectual property portfolio by describing the use of the Company’s lead product candidate, PRP—its proenzyme therapy—for chronic diseases beyond cancer. The biological pathways modulated by PRP to alter cancer cell behavior may also be applicable to conditions such as fibrosis. In particular, the epithelial-to-mesenchymal transition (EMT), a biological process central to embryogenesis and wound healing, plays a critical role in both tumor progression and tissue repair, making it a promising therapeutic target.

“The submission of these two patents represents a significant turning point for Propanc and the commercial potential of PRP for treating chronic diseases such as cancer and fibrosis,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Our planned Phase 1b, First-In-Human study in 2026 will define the target therapeutic dose of PRP, enabling us to explore this unique proenzyme therapy across multiple disease conditions in Phase 2 proof-of-concept studies. This work will be instrumental in establishing PRP as a novel therapeutic approach that encourages cells to differentiate toward normal behavior—without the cytotoxic effects associated with many standard treatments. We are tremendously excited by these developments.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

FAQ

What patents did Propanc (PPCB) request a Spain filing license for on Dec 1, 2025?

Propanc requested a Spain foreign filing license for two provisional patents on methods to treat resistant cancer and fibrosis.

Where will Propanc (PPCB) file the provisional patents and under which entity?

The provisional patents will be filed with IP Australia under Propanc Pty Ltd, the company's Melbourne operating subsidiary.

How does the fibrosis provisional patent expand PRP therapy for Propanc (PPCB)?

The fibrosis provisional describes using PRP proenzyme therapy for chronic organ fibrosis, marking a world‑first expansion beyond cancer in Propanc's IP.

When will Propanc (PPCB) begin human dosing studies for PRP?

Propanc plans a Phase 1b First‑In‑Human study in 2026 to define the target therapeutic dose of PRP.

Do the provisional patents mean immediate patent protection for Propanc (PPCB)?

No; they are provisional patents submitted for filing and have not been granted as issued patents.

Will Propanc (PPCB) seek patent protection beyond Australia for these inventions?

Yes, Propanc expects to file the inventions subsequently in key global jurisdictions.